The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT03441113




Registration number
NCT03441113
Ethics application status
Date submitted
15/02/2018
Date registered
22/02/2018
Date last updated
26/02/2020

Titles & IDs
Public title
Extended Access of Momelotinib in Adults With Myelofibrosis
Scientific title
Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Secondary ID [1] 0 0
2017-004350-42
Secondary ID [2] 0 0
SRA-MMB-4365
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Post-polycythemia Vera Myelofibrosis (Post-PV MF) 0 0
Primary Myelofibrosis (PMF) 0 0
Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) 0 0
Condition category
Condition code
Blood 0 0 0 0
Haematological diseases
Blood 0 0 0 0
Other blood disorders
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - MMB

Other: Cohort 1: Study GS-US-352-0101 - Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-0101 until MMB receives regulatory approval and is commercially available, or development of the product ceases.

Other: Cohort 2: Study GS-US-352-1214 - Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-1214 until MMB receives regulatory approval and is commercially available, or development of the product ceases.

Other: Cohort 3: Study GS-US-352-1154 - Participants will continue to receive the same dosage regimen as in the previous MMB study GS-US-352-1154 until MMB receives regulatory approval and is commercially available, or development of the product ceases..

Other: Cohort 4: Study SRA-MMB-301 - Participants will continue to receive the same dosage regimen as in the previous MMB study SRA-MMB-301 until MMB receives regulatory approval and is commercially available, or development of the product ceases.


Treatment: Drugs: MMB
Tablet(s) administered orally once daily

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants Who Had Access to, and Received the Intervention
Timepoint [1] 0 0
Participants will be assessed every 12 weeks until discontinuation. Participation in this extended access study has been an average of approximately 8 months.

Eligibility
Key inclusion criteria
Key

- Currently enrolled in Studies GS-US-352-0101, GS-US-352-1214, GS-US-352-1154, or
SRA-MMB-301

- Able to comprehend and willing to sign the informed consent form

Key
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Known hypersensitivity to MMB, its metabolites, or formulation excipients

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD,VIC,WA
Recruitment hospital [1] 0 0
Icon Cancer Care Wesley - Hyde Park
Recruitment hospital [2] 0 0
Frankston Hospital - Frankston
Recruitment hospital [3] 0 0
Peter MacCallum Cancer Centre - Parkville
Recruitment hospital [4] 0 0
Royal Perth Hospital - Perth
Recruitment postcode(s) [1] 0 0
4812 - Hyde Park
Recruitment postcode(s) [2] 0 0
3199 - Frankston
Recruitment postcode(s) [3] 0 0
3050 - Parkville
Recruitment postcode(s) [4] 0 0
6160 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
Maryland
Country [5] 0 0
United States of America
State/province [5] 0 0
Massachusetts
Country [6] 0 0
United States of America
State/province [6] 0 0
Minnesota
Country [7] 0 0
United States of America
State/province [7] 0 0
Missouri
Country [8] 0 0
United States of America
State/province [8] 0 0
New York
Country [9] 0 0
United States of America
State/province [9] 0 0
Ohio
Country [10] 0 0
United States of America
State/province [10] 0 0
Wisconsin
Country [11] 0 0
Belgium
State/province [11] 0 0
Antwerp
Country [12] 0 0
Belgium
State/province [12] 0 0
Leuven
Country [13] 0 0
Belgium
State/province [13] 0 0
Liège
Country [14] 0 0
Bulgaria
State/province [14] 0 0
Pleven
Country [15] 0 0
Bulgaria
State/province [15] 0 0
Ruse
Country [16] 0 0
Canada
State/province [16] 0 0
Montréal
Country [17] 0 0
Canada
State/province [17] 0 0
Toronto
Country [18] 0 0
Denmark
State/province [18] 0 0
Aalborg
Country [19] 0 0
Denmark
State/province [19] 0 0
Herlev
Country [20] 0 0
France
State/province [20] 0 0
ILE-De-FRANCE
Country [21] 0 0
France
State/province [21] 0 0
Lille Cedex
Country [22] 0 0
France
State/province [22] 0 0
Marseille
Country [23] 0 0
France
State/province [23] 0 0
Pessac Cedex
Country [24] 0 0
France
State/province [24] 0 0
Pierre Bénite Cedex
Country [25] 0 0
France
State/province [25] 0 0
Toulouse Cedex 9
Country [26] 0 0
Germany
State/province [26] 0 0
Cologne
Country [27] 0 0
Germany
State/province [27] 0 0
Dresden
Country [28] 0 0
Germany
State/province [28] 0 0
Leipzig
Country [29] 0 0
Germany
State/province [29] 0 0
Mainz
Country [30] 0 0
Hungary
State/province [30] 0 0
Budapest
Country [31] 0 0
Hungary
State/province [31] 0 0
Debrecen
Country [32] 0 0
Hungary
State/province [32] 0 0
Kaposvár
Country [33] 0 0
Israel
State/province [33] 0 0
Afula
Country [34] 0 0
Israel
State/province [34] 0 0
Ashkelon
Country [35] 0 0
Israel
State/province [35] 0 0
Haifa
Country [36] 0 0
Israel
State/province [36] 0 0
Jerusalem
Country [37] 0 0
Italy
State/province [37] 0 0
Bologna
Country [38] 0 0
Italy
State/province [38] 0 0
Genova
Country [39] 0 0
Korea, Republic of
State/province [39] 0 0
Seoul
Country [40] 0 0
Netherlands
State/province [40] 0 0
Limburg
Country [41] 0 0
Poland
State/province [41] 0 0
Podkarpacki
Country [42] 0 0
Poland
State/province [42] 0 0
Chorzów
Country [43] 0 0
Poland
State/province [43] 0 0
Lublin
Country [44] 0 0
Poland
State/province [44] 0 0
Malogoskie
Country [45] 0 0
Poland
State/province [45] 0 0
Poznan
Country [46] 0 0
Romania
State/province [46] 0 0
Brasov
Country [47] 0 0
Romania
State/province [47] 0 0
Bucuresti
Country [48] 0 0
Romania
State/province [48] 0 0
Cluj-Napoca
Country [49] 0 0
Romania
State/province [49] 0 0
Iasi
Country [50] 0 0
Singapore
State/province [50] 0 0
Singapore
Country [51] 0 0
Spain
State/province [51] 0 0
Barcelona
Country [52] 0 0
Spain
State/province [52] 0 0
Madrid
Country [53] 0 0
Spain
State/province [53] 0 0
Pamplona
Country [54] 0 0
Spain
State/province [54] 0 0
Zaragoza
Country [55] 0 0
Taiwan
State/province [55] 0 0
Kaohsiung
Country [56] 0 0
United Kingdom
State/province [56] 0 0
Cardiff
Country [57] 0 0
United Kingdom
State/province [57] 0 0
London
Country [58] 0 0
United Kingdom
State/province [58] 0 0
Oxford

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Sierra Oncology, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary objective of this study is to provide extended access of momelotinib (MMB) in
participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential
thrombocythemia myelofibrosis (Post-PV/ET MF) enrolled in studies GS-US-352-0101
(NCT01969838), GS-352-1214 (NCT02101268), GS-US-352-1154 (NCT02124746), SRA-MMB-301 who are
currently receiving treatment with MMB (available as 50mg,100 mg, 150 mg and 200 mg tablets)
and have not experienced progression of disease.
Trial website
https://clinicaltrials.gov/show/NCT03441113
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Sierra Oncology, Inc.
Address 0 0
Sierra Oncology, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT03441113